2ojx › Citations

Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.

García-Alvarez B, de Cárcer G, Ibañez S, Bragado-Nilsson E, Montoya G
Proc Natl Acad Sci U S A 104 3107-12 (2007)
Related entries: 2ogq, 3bzi

Cited: 76 times
EuropePMC logo PMID: 17307877

Abstract

Polo-like kinase (Plk1) is crucial for cell cycle progression through mitosis. Here we present the molecular and structural mechanisms that regulate the substrate recognition of Plk1 and influence its centrosomal localization and activity. Our work shows that Plk1 localization is controlled not only by the polo box domain (PBD); remarkably, the kinase domain is also involved in Plk1 targeting mechanism to the centrosome. The crystal structures of the PBD in complex with Cdc25C and Cdc25C-P target peptides reveal that Trp-414 is fundamental in their recognition regardless of its phosphorylation status. Binding measurements demonstrate that W414F mutation abolishes molecular recognition and diminishes centrosomal localization. Therefore, Plk1 centrosomal localization is not controlled by His-538 and Lys-540, the residues involved in phosphorylated target binding. The different conformations of the loop, which connects the polo boxes in the apo and the PBD-Cdc25C and PBD-Cdc25C-P complex structures, together with changes in the proline adjacent to the phosphothreonine in the target peptide, suggest a regulatory mechanism to detect binding of unphosphorylated or phosphorylated target substrates. Altogether, these data propose a model for the interaction between Plk1 and Cdc25C.

Articles - 2ojx mentioned but not cited (4)

  1. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. García-Alvarez B, de Cárcer G, Ibañez S, Bragado-Nilsson E, Montoya G. Proc Natl Acad Sci U S A 104 3107-3112 (2007)
  2. Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation. Huggins DJ, McKenzie GJ, Robinson DD, Narváez AJ, Hardwick B, Roberts-Thomson M, Venkitaraman AR, Grant GH, Payne MC. PLoS Comput Biol 6 e1000880 (2010)
  3. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors. Sakkiah S, Senese S, Yang Q, Lee KW, Torres JZ. PLoS One 9 e101405 (2014)
  4. Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme. Elling RA, Fucini RV, Hanan EJ, Barr KJ, Zhu J, Paulvannan K, Yang W, Romanowski MJ. Acta Crystallogr Sect F Struct Biol Cryst Commun 64 686-691 (2008)


Reviews citing this publication (20)

  1. Cell cycle kinases as therapeutic targets for cancer. Lapenna S, Giordano A. Nat Rev Drug Discov 8 547-566 (2009)
  2. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Strebhardt K. Nat Rev Drug Discov 9 643-660 (2010)
  3. Polo-like kinases: conservation and divergence in their functions and regulation. Archambault V, Glover DM. Nat Rev Mol Cell Biol 10 265-275 (2009)
  4. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Lens SM, Voest EE, Medema RH. Nat Rev Cancer 10 825-841 (2010)
  5. From Plk1 to Plk5: functional evolution of polo-like kinases. de Cárcer G, Manning G, Malumbres M. Cell Cycle 10 2255-2262 (2011)
  6. Mechanisms of MAVS regulation at the mitochondrial membrane. Jacobs JL, Coyne CB. J Mol Biol 425 5009-5019 (2013)
  7. Polo-box domain: a versatile mediator of polo-like kinase function. Park JE, Soung NK, Johmura Y, Kang YH, Liao C, Lee KH, Park CH, Nicklaus MC, Lee KS. Cell Mol Life Sci 67 1957-1970 (2010)
  8. Understanding the Polo Kinase machine. Archambault V, Lépine G, Kachaner D. Oncogene 34 4799-4807 (2015)
  9. Playing polo during mitosis: PLK1 takes the lead. Combes G, Alharbi I, Braga LG, Elowe S. Oncogene 36 4819-4827 (2017)
  10. PLK1 as an oncology target: current status and future potential. McInnes C, Wyatt MD. Drug Discov Today 16 619-625 (2011)
  11. Molecular dynamics of PLK1 during mitosis. Schmucker S, Sumara I. Mol Cell Oncol 1 e954507 (2014)
  12. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, Bang JK. Mol Cells 32 209-220 (2011)
  13. A survey of the year 2007 literature on applications of isothermal titration calorimetry. Bjelić S, Jelesarov I. J Mol Recognit 21 289-312 (2008)
  14. Current assessment of polo-like kinases as anti-tumor drug targets. Craig SN, Wyatt MD, McInnes C. Expert Opin Drug Discov 9 773-789 (2014)
  15. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Kumar S, Kim J. Biomed Res Int 2015 705745 (2015)
  16. Mechanisms underlying Plk1 polo-box domain-mediated biological processes and their physiological significance. Lee KS, Park JE, Kang YH, Kim TS, Bang JK. Mol Cells 37 286-294 (2014)
  17. New Biological Insights from Better Structure Models. Touw WG, Joosten RP, Vriend G. J Mol Biol 428 1375-1393 (2016)
  18. Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F. Front Oncol 12 903016 (2022)
  19. Cilia and Cancer: From Molecular Genetics to Therapeutic Strategies. Carotenuto P, Gradilone SA, Franco B. Genes (Basel) 14 1428 (2023)
  20. Multiple Roles of PLK1 in Mitosis and Meiosis. Kalous J, Aleshkina D. Cells 12 187 (2023)

Articles citing this publication (52)

  1. A quantitative model of thermal stabilization and destabilization of proteins by ligands. Cimmperman P, Baranauskiene L, Jachimoviciūte S, Jachno J, Torresan J, Michailoviene V, Matuliene J, Sereikaite J, Bumelis V, Matulis D. Biophys J 95 3222-3231 (2008)
  2. Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. de Cárcer G, Escobar B, Higuero AM, García L, Ansón A, Pérez G, Mollejo M, Manning G, Meléndez B, Abad-Rodríguez J, Malumbres M. Mol Cell Biol 31 1225-1239 (2011)
  3. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Liu F, Park JE, Qian WJ, Lim D, Gräber M, Berg T, Yaffe MB, Lee KS, Burke TR. Nat Chem Biol 7 595-601 (2011)
  4. Functional dynamics of Polo-like kinase 1 at the centrosome. Kishi K, van Vugt MA, Okamoto K, Hayashi Y, Yaffe MB. Mol Cell Biol 29 3134-3150 (2009)
  5. Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. Vitour D, Dabo S, Ahmadi Pour M, Vilasco M, Vidalain PO, Jacob Y, Mezel-Lemoine M, Paz S, Arguello M, Lin R, Tangy F, Hiscott J, Meurs EF. J Biol Chem 284 21797-21809 (2009)
  6. Sequestration of Polo kinase to microtubules by phosphopriming-independent binding to Map205 is relieved by phosphorylation at a CDK site in mitosis. Archambault V, D'Avino PP, Deery MJ, Lilley KS, Glover DM. Genes Dev 22 2707-2720 (2008)
  7. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. Liu F, Park JE, Qian WJ, Lim D, Scharow A, Berg T, Yaffe MB, Lee KS, Burke TR. ACS Chem Biol 7 805-810 (2012)
  8. Polo-box domains confer target specificity to the Polo-like kinase family. van de Weerdt BC, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, Medema RH. Biochim Biophys Acta 1783 1015-1022 (2008)
  9. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Śledź P, Stubbs CJ, Lang S, Yang YQ, McKenzie GJ, Venkitaraman AR, Hyvönen M, Abell C. Angew Chem Int Ed Engl 50 4003-4006 (2011)
  10. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. Liao C, Park JE, Bang JK, Nicklaus MC, Lee KS. ACS Med Chem Lett 1 110-114 (2010)
  11. BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis. Singh P, Pesenti ME, Maffini S, Carmignani S, Hedtfeld M, Petrovic A, Srinivasamani A, Bange T, Musacchio A. Mol Cell 81 67-87.e9 (2021)
  12. research-article Self-regulated mechanism of Plk1 localization to kinetochores: lessons from the Plk1-PBIP1 interaction. Lee KS, Oh DY, Kang YH, Park JE. Cell Div 3 4 (2008)
  13. The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. Lobjois V, Jullien D, Bouché JP, Ducommun B. Biochim Biophys Acta 1793 462-468 (2009)
  14. Continuous polo-like kinase 1 activity regulates diffusion to maintain centrosome self-organization during mitosis. Mahen R, Jeyasekharan AD, Barry NP, Venkitaraman AR. Proc Natl Acad Sci U S A 108 9310-9315 (2011)
  15. Dbf4 regulates the Cdc5 Polo-like kinase through a distinct non-canonical binding interaction. Chen YC, Weinreich M. J Biol Chem 285 41244-41254 (2010)
  16. DNA-PKcs associates with PLK1 and is involved in proper chromosome segregation and cytokinesis. Huang B, Shang ZF, Li B, Wang Y, Liu XD, Zhang SM, Guan H, Rang WQ, Hu JA, Zhou PK. J Cell Biochem 115 1077-1088 (2014)
  17. Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding. Schwarz J, Schmidt S, Will O, Koudelka T, Köhler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, Schwake M, Rose-John S, Chalaris A. J Biol Chem 289 3080-3093 (2014)
  18. Henipavirus V protein association with Polo-like kinase reveals functional overlap with STAT1 binding and interferon evasion. Ludlow LE, Lo MK, Rodriguez JJ, Rota PA, Horvath CM. J Virol 82 6259-6271 (2008)
  19. Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. Jeong K, Jeong JY, Lee HO, Choi E, Lee H. Dev Biol 345 34-48 (2010)
  20. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Kirkland LO, McInnes C. Biochem Pharmacol 77 1561-1571 (2009)
  21. Independent modulation of the kinase and polo-box activities of Cdc5 protein unravels unique roles in the maintenance of genome stability. Ratsima H, Ladouceur AM, Pascariu M, Sauvé V, Salloum Z, Maddox PS, D'Amours D. Proc Natl Acad Sci U S A 108 E914-23 (2011)
  22. The condensin component NCAPG2 regulates microtubule-kinetochore attachment through recruitment of Polo-like kinase 1 to kinetochores. Kim JH, Shim J, Ji MJ, Jung Y, Bong SM, Jang YJ, Yoon EK, Lee SJ, Kim KG, Kim YH, Lee C, Lee BI, Kim KT. Nat Commun 5 4588 (2014)
  23. Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies. Wachowicz P, Fernández-Miranda G, Marugán C, Escobar B, de Cárcer G. Bioessays 38 Suppl 1 S96-S106 (2016)
  24. Structure-function relationship of the Polo-like kinase in Trypanosoma brucei. Yu Z, Liu Y, Li Z. J Cell Sci 125 1519-1530 (2012)
  25. Coupling of Polo kinase activation to nuclear localization by a bifunctional NLS is required during mitotic entry. Kachaner D, Garrido D, Mehsen H, Normandin K, Lavoie H, Archambault V. Nat Commun 8 1701 (2017)
  26. The methyltransferase SETD6 regulates Mitotic progression through PLK1 methylation. Feldman M, Vershinin Z, Goliand I, Elia N, Levy D. Proc Natl Acad Sci U S A 116 1235-1240 (2019)
  27. Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Shen M, Cai Y, Yang Y, Yan X, Liu X, Zhou T. Cell Res 23 1284-1295 (2013)
  28. Centrosome-Dependent Bypass of the DNA Damage Checkpoint by the Polo Kinase Cdc5. Ratsima H, Serrano D, Pascariu M, D'Amours D. Cell Rep 14 1422-1434 (2016)
  29. In-silico screening of cancer associated mutation on PLK1 protein and its structural consequences. Kamaraj B, Rajendran V, Sethumadhavan R, Purohit R. J Mol Model 19 5587-5599 (2013)
  30. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. McInnes C, Estes K, Baxter M, Yang Z, Farag DB, Johnston P, Lazo JS, Wang J, Wyatt MD. Mol Cancer Ther 11 1683-1692 (2012)
  31. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. Srinivasrao G, Park JE, Kim S, Ahn M, Cheong C, Nam KY, Gunasekaran P, Hwang E, Kim NH, Shin SY, Lee KS, Ryu E, Bang JK. PLoS One 9 e107432 (2014)
  32. Identification of a nuclear localization signal in the polo box domain of Plk1. Lee MS, Huang YH, Huang SP, Lin RI, Wu SF, Li C. Biochim Biophys Acta 1793 1571-1578 (2009)
  33. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Abdelfatah S, Berg A, Huang Q, Yang LJ, Hamdoun S, Klinger A, Greten HJ, Fleischer E, Berg T, Wong VKW, Efferth T. Acta Pharm Sin B 9 1021-1034 (2019)
  34. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Qian WJ, Park JE, Lee KS, Burke TR. Bioorg Med Chem Lett 22 7306-7308 (2012)
  35. Phospho-Pon Binding-Mediated Fine-Tuning of Plk1 Activity. Zhu K, Shan Z, Zhang L, Wen W. Structure 24 1110-1119 (2016)
  36. Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics. Byrne DP, Clarke CJ, Brownridge PJ, Kalyuzhnyy A, Perkins S, Campbell A, Mason D, Jones AR, Eyers PA, Eyers CE. Biochem J 477 2451-2475 (2020)
  37. A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation. Sharma P, Mahen R, Rossmann M, Stokes JE, Hardwick B, Huggins DJ, Emery A, Kunciw DL, Hyvönen M, Spring DR, McKenzie GJ, Venkitaraman AR. Sci Rep 9 15930 (2019)
  38. Interaction between human papillomavirus type 5 E2 and polo-like kinase 1. Wang WS, Lee MS, Tseng CE, Liao IH, Huang SP, Lin RI, Li C. J Med Virol 81 536-544 (2009)
  39. In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide. Kim SM, Yoon S, Choi N, Hong KS, Murugan RN, Cho G, Ryu EK. Biomaterials 33 6915-6925 (2012)
  40. Structural basis for recognition of Emi2 by Polo-like kinase 1 and development of peptidomimetics blocking oocyte maturation and fertilization. Jia JL, Han YH, Kim HC, Ahn M, Kwon JW, Luo Y, Gunasekaran P, Lee SJ, Lee KS, Kyu Bang J, Kim NH, Namgoong S. Sci Rep 5 14626 (2015)
  41. Calmodulin activation of polo-like kinase 1 is required during mitotic entry. Dai G, Qian Y, Chen J, Meng FL, Pan FY, Shen WG, Zhang SZ, Xue B, Li CJ. Biochem Cell Biol 91 287-294 (2013)
  42. Computational design of targeted inhibitors of polo-like kinase 1 (plk1). Jani KS, Dalafave DS. Bioinform Biol Insights 6 23-31 (2012)
  43. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. Baxter M, Chapagai D, Craig S, Hurtado C, Varghese J, Nurmemmedov E, Wyatt MD, McInnes C. ChemMedChem 15 1058-1066 (2020)
  44. Congress Structures and diseases. Wendt KU, Weiss MS, Cramer P, Heinz DW. Nat Struct Mol Biol 15 117-120 (2008)
  45. AMPKα2 activation by an energy-independent signal ensures chromosomal stability during mitosis. Lu J, Huang Y, Zhan L, Wang M, Xu L, Mullen M, Zang J, Fang G, Dou Z, Liu X, Liu W, Garcia-Barrio M, Yao X. iScience 24 102363 (2021)
  46. Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1. Huggins DJ, Hardwick BS, Sharma P, Emery A, Laraia L, Zhang F, Narvaez AJ, Roberts-Thomson M, Crooks AT, Boyle RG, Boyce R, Walker DW, Mateu N, McKenzie GJ, Spring DR, Venkitaraman AR. ACS Omega 5 822-831 (2020)
  47. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Abdelfatah S, Fleischer E, Klinger A, Wong VKW, Efferth T. Invest New Drugs 38 1-9 (2020)
  48. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Ryu S, Park JE, Ham YJ, Lim DC, Kwiatkowski NP, Kim DH, Bhunia D, Kim ND, Yaffe MB, Son W, Kim N, Choi TI, Swain P, Kim CH, Lee JY, Gray NS, Lee KS, Sim T. J Med Chem 65 1915-1932 (2022)
  49. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C. Eur J Med Chem 227 113926 (2022)
  50. Targeted delivery of a phosphopeptide prodrug inhibits the proliferation of a human glioma cell line. Kim SM, Yoon SM, Yim MS, Cho G, Ryu EK. Amino Acids 45 1149-1156 (2013)
  51. Hornerin mediates phosphorylation of the polo-box domain in Plk1 by Chk1 to induce death in mitosis. Song H, Kim EH, Hong J, Gwon D, Kim JW, Bae GU, Jang CY. Cell Death Differ 30 2151-2166 (2023)
  52. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition. Park JE, Kirsch K, Lee H, Oliva P, Ahn JI, Ravishankar H, Zeng Y, Fox SD, Kirby SA, Badhwar P, Andresson T, Jacobson KA, Lee KS. Proc Natl Acad Sci U S A 120 e2305037120 (2023)


Quick links